Effects of Placental Extract on Cell Proliferation, Type I Collagen Production, and ALP Secretion in Human Osteosarcoma Cell Line Saos-2

Abstract

Porcine placenta extract (P-placenta) is widely applied in medicine and cosmetics. However, few studies have examined the effect of the extract on the cellular behavior of the osteoblastic cell line Saos-2. Here, we demonstrated that P-placenta enhances the proliferation, collagen type I production, and alkaline phosphatase (ALP) secretion of Saos-2 in vitro. Proliferation of Saos-2 was assessed by MTT and DNA synthesis assays. Type I collagen production and ALP secretion were evaluated using enzyme-linked immunosorbent assay and ALP assays. The cells were treated with/without 20, 200 and 2000 g/ml of P-placenta for 24 h. We found that 200 g/ml P-placenta significantly induced the proliferation of Saos-2 and enhanced type I collagen production and ALP secretion. The results indicate that P-placenta controls the cellular behavior of osteoblasts, resulting in the secretion of early bone-related biomarkers.

Highly elastic 3D-printed gelatin/HA/placental-extract scaffolds for bone tissue engineering

“…Nevertheless, similar results proposing the osteogenic potential of placenta extract have been reported. Elevation of collagen type I synthesis and ALP activities of osteosarcoma cell line (Saos-2) by porcine placental extract were observed by Wang et al 31 . Additionally, research on the effects of placental extract in ovariectomized (OVX) mice reported that placental extract could enhance bone formation in OVX mice and augment ALP activity in osteoblast-like cells 67 .…”

“…In addition, expression of the osteogenic genes ALP, Runx2, BMP2, OPN , and OCN is shown in Figure 6 H, and the primary and late osteogenic genes were significantly upregulated in the hASCs cultured on the G/H/hPE scaffold compared to the G/H scaffold ( ALP : 3.4-fold, Runx2 : 3.9-fold, BMP2 : 1.7-fold, OPN : 2.4-fold, and OCN : 4.8-fold at day 21). Although the placental extract (PE) has been widely used as a therapeutic treatment, the osteogenic differentiation mechanism of PE remains to be unclear 31 . Nevertheless, similar results proposing the osteogenic potential of placenta extract have been reported.…”

“…For rat mastoid obliteration, gelatin/HA scaffolds (2 × 2 × 2 mm 3 , 3.54 ± 0.24 mg) with 100 μl of PBS (G/H, control group) and gelatin/HA scaffolds with hPE (100 μl, 2 mg/ml) (G/H/hPE, experimental group) were prepared. The dose of hPE was selected based on the other research 31 , 70 . Clean surgical drapes are employed in the infra-auricular area to provide a physical barrier that protects the surgical field from contamination after antiseptic painting using a povidone after shaving the hairs around the auricle using an electric clipper.…”

“…Furthermore, to enhance the bioactive properties of the fabricated gelatin/HA scaffold, human placental extracts (hPE), which contain various growth factors and cytokines inducing outstanding cellular activities such as cell growth and differentiation, were used 30 . Although the hPE have been widely used for the various therapy, to the best of our knowledge, the osteogenic potential of hPE have not been clearly proved 31 . To observe the osteogenic activities of the fabricated gelatin/HA/hPE (G/H/hPE) scaffolds, the expression of various osteogenic genes in human adipose stem cells (hASCs) was assessed for several culture periods.…”

Amphiphilic dextran-vinyl laurate-based nanoparticles: formation, characterization, encapsulation, and cytotoxicity on human intestinal cell line

“…Here, we report the synthesis and characterization of amphiphilic dextran-vinyl laurate-based polymer (Dex-L) and evaluate its efficacy as the encapsulation platform for porcine placenta hydrolysate. Porcine placenta extract has been widely reported to possess various therapeutic benefits, including enhancement of cell proliferation (Imamura et al 2017), antioxidant activity (Tang et al 2013), and immunostimulation in pigs (Lee et al 2013). However, oral application of porcine placenta hydrolysate is susceptible to protein degradation that can occur in the digestive system and will benefit from an effective encapsulation technology.…”